Repetitive Transcranial Magnetic Stimulation and Intermittent Theta Burst (iTBS) in Schizophrenia
NCT ID: NCT01315587
Last Updated: 2015-09-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
30 participants
INTERVENTIONAL
2011-01-31
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
iTBS on Negative Symptoms and Cognitive Function in Schizophrenia
NCT05137158
Theta-burst rTMS in Schizophrenia to Ameliorate Negative and Cognitive Symptoms
NCT05100888
The Study of Effectiveness Repetitive Transcranial Magnetic Stimulation in Bipolar Depression
NCT01932749
Treating Social Cognition With Theta Burst Stimulation: a Multicentric Study
NCT02479919
nTMS for Negative Symptom in Schizophrenia
NCT06642675
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
intermittent theta burst stimulation
repetitive Transcranial Magnetic Stimulation (Magstim rapid2 )
* 3 pulses at 50Hz repeated each 200 ms for 2 seconds
* 80% MT
* 20 days treatment
repetitive Transcranial Magnetic Stimulation
repetitive Transcranial Magnetic Stimulation (Magstim rapid2)
LDLPFC 110% MT 15 Hz 20 days
Sham TMS
repetitive Transcranial Magnetic Stimulation(Magstim rapid2)
Placebo treatment: Sham coil
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
repetitive Transcranial Magnetic Stimulation (Magstim rapid2 )
* 3 pulses at 50Hz repeated each 200 ms for 2 seconds
* 80% MT
* 20 days treatment
repetitive Transcranial Magnetic Stimulation (Magstim rapid2)
LDLPFC 110% MT 15 Hz 20 days
repetitive Transcranial Magnetic Stimulation(Magstim rapid2)
Placebo treatment: Sham coil
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The diagnosis of schizophrenia according to DSM-IV-TR
3. Completion of consent form
4. Being under supervision of a psychiatrist,
5. Being able to adhere to treatment schedule,
6. Having stable symptoms as defined by not requiring a change in antipsychotic medication for at least 4 weeks or at least 2 weeks for psychotropic agents prior to entering the Study
Exclusion Criteria
2. Cardiac pacemaker
3. Drug pumps
4. Acute heart attack
5. The risk of seizure with any reasons
6. The history of epilepsy or seizure in the first relatives
7. Any metal in head
8. Brain trauma
9. Pregnancy
10. Breastfeeding
11. Drug dependency
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Tehran
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
reza kazemi
Researcher
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Atieh Clinical Neuroscience Center (ACNC)
Tehran, Tehran Province, Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23456
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.